Clinical trial · Interventional
The Impact of Treating Minor Uterine Cavity Abnormalities Diagnosed by Office Hysteroscopy in Unselected In Vitro Fertilization (IVF) Cases
Comparative Controlled Trial of Treatment of Minor Unexpected Uterine Cavity Abnormalities Diagnosed by Office Hysteroscopy Screening in Women Indicated for IVF
NCT00830401CI-TRIAL-00018145terminatedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Abnormality prevalence revealed to be much lower than expected.
Summary
Brief summary (as posted)
This is a comparative, controlled trial to evaluate the impact of treating undetected, asymptomatic, predefined minor uterine cavity abnormalities on the success of IVF treatment.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Minor Intra-uterine Abnormalities | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Ofloxacinum/Doxycycline | Drug | — | UNRESOLVED |
| Treatment of predefined abnormality by hysteroscopic surgery | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- NO_INTERVENTION
- label
- 1
- description
- One or more of the predefined minor intra-uterine abnormalities have been detected, but not treated during hysteroscopy.
- type
- ACTIVE_COMPARATOR
- label
- 2
- description
- One or more of the predefined minor intra-uterine abnormalities have been detected and treated during hysteroscopy.
- interventionNames
- Procedure: Treatment of predefined abnormality by hysteroscopic surgery
- Drug: Ofloxacinum/Doxycycline
Primary outcomes (1)
- measure
- Cumulative implantation rate
- timeFrame
- One year
Secondary outcomes (2)
Eligibility
Eligibility (as posted)
- Sex
- Female
- Maximum age
- 36 Years
Show eligibility criteria text
Inclusion Criteria: * Normal Transvaginal Ultrasound * No prior hysteroscopy * Regular menstrual cycle * Single embryo transfer * BMI between 18 and 29 * Presence of both ovaries * Primary or secondary infertility * Women indicated for a first IVF/ICSI cycle Exclusion Criteria: * Recurrent miscarriage * Prior hysteroscopic treatments * Endometriosis \> AFS Stage II * Meno-metrorrhagia (defined as any intermenstrual loss of blood) * Submucosal/Intracavitary Fibroids taking more than 50% of the cavity * Hydrosalpinx * FSH/LH \> 12IU/L on day 3 * Polyps taking more than 50% of the cavity * Severe adhesions \> grade II
References
Publications (1)
- DERIVEDSmit JG, Kasius JC, Eijkemans MJ, Veersema S, Fatemi HM, Santbrink van EJ, Campo R, Broekmans FJ. The international agreement study on the diagnosis of the septate uterus at office hysteroscopy in infertile patients. Fertil Steril. 2013 Jun;99(7):2108-13.e2. doi: 10.1016/j.fertnstert.2013.02.027. Epub 2013 Mar 13. PMID 23499151